# Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.

Study · id `cardio:ct-nct05817851` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05817851](<https://clinicaltrials.gov/study/NCT05817851>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05817851

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 234 participants.

## Technical summary

Registry record NCT05817851. Randomized; no masking; primary purpose treatment. Start 2023-12-27 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 234 participants (planned count; ClinicalTrials.gov record NCT05817851, source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)
- Started: 2023-12-27 (actual) (ClinicalTrials.gov record NCT05817851, source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)
- Primary completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT05817851, source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)
- Completion: 2028-01-24 (anticipated) (ClinicalTrials.gov record NCT05817851, source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT05817851, source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05817851-2026-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
- Acronym: VICEPAC
- Condition: Cardiac Arrest
- Intervention (Drug): Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
- Intervention (Drug): standard treatment
- Lead sponsor: Centre Hospitalier de Bethune
- Lead sponsor class: NETWORK
- Collaborator: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Collaborator class: OTHER
- Collaborator: University Hospital, Lille
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)
- Registry lists this organization as a collaborator: University Hospital, Lille (`cardio:org-university-hospital-lille`)

## Provenance

Content hash: 2a1f0d4cecea4630b5bb49bdfa165f9f2d9c92840040a98f36b61825d05da24b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
